MedTrace Logo

A Second Dose of Measles Vaccine (MV) in the Second Year of Life

NCT02943681 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3812

Last updated 2024-01-19

No results posted yet for this study

Summary

This study evaluates the non-specific effects on child mortality and morbidity of a second dose of measles in the second year of life. Half of the study participants will receive a second dose of measles vaccine at 18 months of age while the other half will receive a second dose of measles by 4 years of age or at the end of the study.

Conditions

  • Child Mortality
  • Child Morbidity

Interventions

BIOLOGICAL

Measles vaccine

Sponsors & Collaborators

  • Bandim Health Project

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Months
Max Age
24 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2020-05-31
Completion
2021-05-31

Countries

  • Guinea-Bissau

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02943681 on ClinicalTrials.gov